MX2022009263A - Metodos para la maduracion de una fistula arteriovenosa. - Google Patents

Metodos para la maduracion de una fistula arteriovenosa.

Info

Publication number
MX2022009263A
MX2022009263A MX2022009263A MX2022009263A MX2022009263A MX 2022009263 A MX2022009263 A MX 2022009263A MX 2022009263 A MX2022009263 A MX 2022009263A MX 2022009263 A MX2022009263 A MX 2022009263A MX 2022009263 A MX2022009263 A MX 2022009263A
Authority
MX
Mexico
Prior art keywords
maturing
avf
methods
arteriovenous fistula
active agent
Prior art date
Application number
MX2022009263A
Other languages
English (en)
Inventor
Katalin Kauser
Original Assignee
Alucent Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alucent Biomedical Inc filed Critical Alucent Biomedical Inc
Publication of MX2022009263A publication Critical patent/MX2022009263A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621—Extra-corporeal blood circuits
    • A61M1/3653—Interfaces between patient blood circulation and extra-corporal blood circuit
    • A61M1/3655—Arterio-venous shunts or fistulae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente descripción proporciona métodos novedosos para madurar una AVF en el momento de la creación de una fístula que comprende administrar a una AVF una composición que comprende al menos un agente activo elegido entre un Compuesto de fórmula (I) y sales farmacéuticamente aceptables del mismo e iluminar al menos un agente activo agente sobre dicha AVF con luz visible, como, por ejemplo, luz de 450 nm.
MX2022009263A 2020-01-29 2021-01-28 Metodos para la maduracion de una fistula arteriovenosa. MX2022009263A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062967465P 2020-01-29 2020-01-29
PCT/US2021/015439 WO2021154958A1 (en) 2020-01-29 2021-01-28 Methods for maturing an arteriovenous fistula

Publications (1)

Publication Number Publication Date
MX2022009263A true MX2022009263A (es) 2022-10-28

Family

ID=74673386

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009263A MX2022009263A (es) 2020-01-29 2021-01-28 Metodos para la maduracion de una fistula arteriovenosa.

Country Status (10)

Country Link
US (1) US20230089273A1 (es)
EP (1) EP4096658A1 (es)
JP (1) JP2023512169A (es)
KR (1) KR20220132549A (es)
CN (1) CN114980888A (es)
AU (1) AU2021212750A1 (es)
BR (1) BR112022014842A2 (es)
CA (1) CA3167236A1 (es)
MX (1) MX2022009263A (es)
WO (1) WO2021154958A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023538892A (ja) * 2020-08-20 2023-09-12 アルーセント バイオメディカル，インコーポレイティッド 二量体ナフタルイミドコーティング
US20230398334A1 (en) * 2022-06-10 2023-12-14 Alucent Biomedical, Inc. Coated balloon catheter for treating arteriovenous fistula and methods of using same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410505B1 (en) * 1999-06-28 2002-06-25 Microbiomed Corp. Dimeric non-azo naphthalimides and uses for the same
CN101166484A (zh) * 2004-12-08 2008-04-23 渗透治疗有限公司 治疗和管理斑块疾病的材料和方法
US10959995B2 (en) * 2013-03-15 2021-03-30 Alumend, Llc Methods of acute restoration of vascular compliance
EP3809983A4 (en) * 2018-06-22 2021-09-01 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR IMPROVING THE MATURATION OF ARTERIOVENOUS FISTULA AND MAINTAINING THE FUNCTIONALITY OF ARTERIOVENOUS FISTULA

Also Published As

Publication number Publication date
KR20220132549A (ko) 2022-09-30
EP4096658A1 (en) 2022-12-07
BR112022014842A2 (pt) 2022-09-27
AU2021212750A1 (en) 2022-07-21
CA3167236A1 (en) 2021-08-05
CN114980888A (zh) 2022-08-30
WO2021154958A1 (en) 2021-08-05
JP2023512169A (ja) 2023-03-24
US20230089273A1 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
TN2021000028A1 (en) Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject
MX2022009263A (es) Metodos para la maduracion de una fistula arteriovenosa.
MX2020007633A (es) Péptidos macrocíclicos contra acinetobacter baumannii.
EA200501098A1 (ru) Антибактериальные агенты
BR0313160A (pt) Composto, composição farmacêutica, métodos para tratar uma condição e um neoplasmo suscetìvel em um animal em um animal, processo para preparar um composto e uso de um composto
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
ATE455786T1 (de) 6-11 bicyclische ketolidderivate
BR0315630A (pt) Administração de combinação de uma indolinona com um agente quimioterapêutico para distúrbios de proliferação celular
BRPI0510059A (pt) inibidores da transcriptase reversa não-nucleosìdica
BR0311460A (pt) Composição farmacêutica de liberação modificada, uso de uma formulação, e, método para tratar um distúrbio cardiovascular em um paciente
CR20230052A (es) Combinaciones para el tratamiento de cáncer.
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
BR112013010890A2 (pt) método de tratamento ou prevenção de, pelo menos, uma doença ou condição e para reduzir o desenvolvimento de aterosclerose num sujeito deles necessitado e uso de composto
WO2019207257A8 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
DK1781299T3 (da) Anti-inflammatoriske midler
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.
AU2019375825A8 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
MX2023003846A (es) Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo.
MX2021003606A (es) Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
BR0311363A (pt) Formulação farmacêutica de liberação imediata, uso da mesma, e, método para tratar um distúrbio cardiovascular em um paciente
MX2022012575A (es) Compuestos para usarse para tratar la enfermedad de huntington.
BRPI0414822A (pt) método de inibir a produção de lipoproteìna remanescente
AR040441A1 (es) Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento
MX2022015524A (es) Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas.